Holen Sie sich die Stockscreener-App
1.0451
5.05%
-0.0449
Schlusskurs vom Vortag:
$1.09
Offen:
$1.11
24-Stunden-Volumen:
743.14K
Relative Volume:
0.57
Marktkapitalisierung:
$264.29M
Einnahmen:
$14.78M
Nettoeinkommen (Verlust:
$-64.01M
KGV:
-3.6377
EPS:
-0.2873
Netto-Cashflow:
$-22.59M
1W Leistung:
-6.76%
1M Leistung:
-5.91%
6M Leistung:
-41.53%
1J Leistung:
-18.50%
1-Tages-Spanne:
$1.03
$1.12
1-Wochen-Bereich:
$1.03
$1.16
52-Wochen-Spanne:
$1.00
$2.09
Lineage Cell Therapeutics Inc Stock (LCTX) Company Profile
Firmenname
Lineage Cell Therapeutics Inc
Sektor
Branche
Telefon
510-871-4188
Adresse
2173 Salk Avenue, Suite 200, Carlsbad, CA
Compare LCTX vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LCTX
Lineage Cell Therapeutics Inc
|
1.045 | 275.67M | 14.78M | -64.01M | -22.59M | -0.2873 |
VRTX
Vertex Pharmaceuticals Inc
|
522.11 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.76 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,004.25 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.30 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.67 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lineage Cell Therapeutics Inc Stock (LCTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-20 | Eingeleitet | Craig Hallum | Buy |
| 2022-11-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-06-14 | Eingeleitet | B. Riley Securities | Buy |
| 2021-08-19 | Eingeleitet | Noble Capital Markets | Outperform |
| 2021-03-31 | Eingeleitet | Cantor Fitzgerald | Overweight |
Lineage Cell Therapeutics Inc Aktie (LCTX) Neueste Nachrichten
Lineage Cell Therapeutics Announces Issuance of Patent Underlying Its AlloSCOPE™ 5D Manufacturing Platform - BioSpace
Lineage Cell Therapeutics Announces Issuance of Patent Underlying Its AlloSCOPE 5D Manufacturing Platform - investingnews.com
LCTX Looks 6.9% Undervalued on GF Value™ as Stem Cell Patent Boo - GuruFocus
Lineage Cell Therapeutics: Balancing An Out-Licensed Pipeline Against Clinical Risk - Seeking Alpha
Lineage Cell Therapeutics Inc. (LCTX) Peer Comparison – Compare with Others - Value Research
Lineage Cell Therapeutics Inc (NYSE: LCTX) Stock Price, News & Analysis - kalkine.ca
LCTX Q2 2026 Earnings: Wider-Than-Expected Loss Keeps Focus on Cell Therapy PipelineEPS Growth Rate - Vinanet
LCTX Q2 2026 Earnings: Slight EPS Miss Overshadowed as Shares Rise $0.94Revenue Surprise History - Vinanet
LCTX Q2 2026 Earnings: Modest EPS Miss Overshadowed by Clinical-Stage FocusOne-Time Loss Impact - Vinanet
Lineage Cell Therapeutics (LCTX) Q2 2026 Earnings Call Transcript - AOL.ca
Lineage Cell Therapeutics (LCTX) Falls 3.6% to $1.06 as Biotech Sentiment WeighsDealer Gamma - vinanet.vn
Lineage Cell Therapeutics Q3 EPS Reduced by HC Wainwright - MarketBeat
Lineage Cell Therapeutics (LCTX) Climbs 3.18% to $1.14 as Buyers Defend Key SupportRisk Reward Setups - vinanet.vn
Lineage Cell Therapeutics Q2 Earnings Call Highlights - MarketBeat
CCORF Maintains Lineage Cell Therapeutics(LCTX.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Lineage Cell Therapeutics, Inc. (LCTX) stock price, news, quote and history - Yahoo Finance Australia
Lineage Cell Therapeutics Balances Progress and Risk - TipRanks
Lineage Cell Therapeutics (LCTX) Stock Faces Cash Burn Despite Paper Profit - Sahm
Lineage Cell Therapeutics Inc (LCTX) Stock News Today - TradingKey
Lineage Cell Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - biospace.com
Lineage Cell Therapeutics Inc (LCTX) (Q2 2026) Earnings Call Hig - GuruFocus
LCTX Looks 13.7% Undervalued on GF Value™ - GuruFocus
Transcript : Lineage Cell Therapeutics, Inc., Q2 2026 Earnings Call, Aug 06, 2026 - marketscreener.com
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Posts Quarterly Earnings Results, Hits Estimates - MarketBeat
Earnings call transcript: Lineage Cell Therapeutics posts Q2 2026 profit, extends runway - Investing.com
Lineage Cell (LCTX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Lineage Cell: Q2 Earnings Snapshot - marketscreener.com
[10-Q] Lineage Cell Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Lineage Cell Therapeutics (LCTX) Edges Higher to $1.13, Holding Key Support in Tight Trading RangeEarly Entry Signals - dars.gov.et
3 Penny Stocks With Market Caps Larger Than $40M To Watch - webull.com
Lineage Cell Therapeutics (LCTX) Nudges Higher, Consolidating Between $1.06 Support and $1.18 ResistanceGamma Flip Level - dars.gov.et
Lineage Cell Therapeutics (LCTX) to Post Earnings on Thursday - MarketBeat
Lineage Cell Therapeutics, Inc. Revenue Breakdown – AMEX:LCTX - TradingView
Earnings Preview: LCTX to Report Financial Results Post-market on August 06 - Moomoo
Lineage Cell Therapeutics to announce Q2 2026 results on August 6 with business update call - Traders Union
Lineage Cell Therapeutics (LCTX) Holds Above $1.04 Support After 0.90% PullbackBPI Bull Confirmed - vinanet.vn
Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026 - Business Wire
BlackRock, Inc. (LCTX) discloses 5.3% beneficial ownership in Lineage Cell - Stock Titan
Lineage Cell Therapeutics Inc (LCTX) Income Statement - TradingKey
Lineage Cell Therapeutics Inc (LCTX) Cash Flow - TradingKey
Lineage Cell Therapeutics Inc - TradingKey
LCTX|Lineage Cell Therapeutics Inc|Price:1.035|Chg%:+0.005 - TradingKey
Lineage Cell Therapeutics Inc (LCTX) Balance Sheet - TradingKey
Lineage Cell Therapeutics Inc (LCTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lineage Cell Therapeutics Inc (LCTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Lineage Cell Therapeutics Inc (LCTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Lineage Cell Therapeutics (LCTX) Slips 3.74% as Stock Tests Key Support LevelsMcClellan Summation - dars.gov.et
Lineage Cell Therapeutics, Inc. Revenue Breakdown – SWB:BT3 - TradingView
Lineage Cell Therapeutics, Inc. Revenue Breakdown – LS:A2PP89 - TradingView
LCTX|Lineage Cell Therapeutics Inc|Price:1.030|Chg%:-0.035 - TradingKey
Finanzdaten der Lineage Cell Therapeutics Inc-Aktie (LCTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.63%
3.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):